91.22 +0.16 (0.18%)
After hours: 5:16PM EDT
|Bid||80.93 x 100|
|Ask||93.22 x 100|
|Day's Range||89.16 - 94.38|
|52 Week Range||51.62 - 99.82|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||99.25|
"This is a shift in the entire treatment paradigm," Agios CEO David Schenkein told the Business Journal. "This is obviously a very exciting day for Agios, but even more so, for patients who now have a treatment that wasn't previously available."
Agios Pharmaceuticals Inc said on Friday its oral drug to treat a type of leukemia was approved by the U.S. health regulator. The drug, Tibsovo, was approved on the basis of an early-stage trial to treat patients with acute myeloid leukemia - a cancer of the blood and bone marrow - whose disease has been resistant to treatment or has relapsed. There are about 20,000 new cases of acute myeloid leukemia in the United States each year, the company said.
CAMBRIDGE, Mass., July 20, 2018--- Approval of TIBSOVO ® was Based on Phase 1 Study Results, Including Rate and Duration of Complete Remission and CR with Partial Hematologic Recovery and Rate of Conversion ...
Five of the six analysts covering Athenex (ATNX) in July gave the stock a “buy” rating, and one analyst gave it a “hold” rating. The mean rating for Athenex stock is 2.17 with a target price of $28.33. In July, two of the ten analysts covering Agios Pharmaceuticals (AGIO) gave the stock a “strong buy” rating, six analysts gave it a “buy” rating, and two analysts gave Agios a “hold” rating.
NEW YORK, June 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Biglari ...
Agios (AGIO) and CStone Pharmaceticals sign an exclusive collaboration and license agreement for the development and commercialization of its lead pipeline candidate Tibsovo.
June 26 (Reuters) - Agios Pharmaceuticals Inc: * AGIOS AND CSTONE PHARMACEUTICALS ANNOUNCE EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE IVOSIDENIB IN GREATER CHINA * AGIOS ...
Discovered and developed by Agios, ivosidenib is an investigational, first-in-class, oral, targeted inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) enzyme. CStone Pharmaceuticals will be responsible for conducting the development and commercialization activities for ivosidenib in hematologic and solid tumor indications in the Territory, with an initial focus in acute myeloid leukemia (AML) and cholangiocarcinoma.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 20) Agios Pharmaceuticals Inc (NASDAQ: AGIO )(announced initiation ...
Agios Pharmaceuticals, Inc. (AGIO), initiates a phase III ACTIVATE study which will evaluateits lead rare genetic diseases candidate, AG-348 in patients with PK deficiency who do not receive regular blood transfusions.
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the initiation of the Phase 3 ACTIVATE trial evaluating AG-348, a first-in-class, selective, small molecule activator of the pyruvate kinase-R (PKR) enzyme. ACTIVATE is a randomized, placebo-controlled trial that will enroll approximately 80 adults with pyruvate kinase (PK) deficiency who do not receive regular blood transfusions. “AG-348 is the first potential treatment for PK deficiency that targets the underlying cause of a patient’s anemia and has demonstrated robust and sustained hemoglobin increases in adults with this disease who are not regularly transfused,” said Chris Bowden, M.D., chief medical officer of Agios.
As Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closes at new highs, analysts are gushing over the company’s prospects. What is it about Agios stock that has the experts bullish on the company? Markets speculated that Celgene Corporation (NASDAQ:CELG) would buy Agios or Jounce Therapeutics, Inc. (NASDAQ:JNCE) back in April.
-Safety Profile of Combination Therapies Consistent with Single Agent IDHm Inhibitors and Azacitidine-. -ORR of 78%, CR Rate of 44% and CR/CRi/CRp Rate of 65% in the Ivosidenib Arm; Molecular Clearance ...
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
-In 179 Relapsed or Refractory IDH1m AML Patients, Primary Endpoint of CR+ CRh Rate of 31.8% with a Median Duration CR+ CRh of 8.2 Months-. -Updated Data Suggest that R/R AML Patients with IDH1-Mutation ...
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today presented the first data from the ongoing Phase 1 study evaluating single agent AG-881 in advanced glioma and other solid tumors. The data were featured in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. AG-881 is an investigational, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1) and IDH2 enzymes, which was designed for enhanced brain penetrance for development in IDH-mutant glioma.
NEW YORK, NY / ACCESSWIRE / June 1, 2018 / U.S. markets closed sharply lower on Thursday as the U.S. decided to impose tariffs on steel and aluminum imports from Canada, Mexico and the European Union. ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 31) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) (Piper Jaffray initiated ...
Agios Pharmaceuticals Inc (NASDAQ: AGIO ), a pharmaceutical company that focuses on the field cellular metabolism to treat cancer and rare genetic diseases, is a stock investors should "own for the ...
AGIO has an attractive set of charts and indicators so let's see if this new name is worth buying. In this daily bar chart of AGIO, below, we can see that prices have been in an uptrend the past 12 months and have almost doubled from their lows of last June. The daily On-Balance-Volume (OBV) line has also been positive for the past year and tells us that buyers of AGIO have been more aggressive than the sellers.
NEW YORK, May 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Agios ...
–Updated Data From Ivosidenib Phase 1 Expansion in IDH1m R/R AML and the First Data from the AG-881 Phase 1 Study in IDHm Glioma to be Highlighted in Oral Presentations–. –New Data From Fully Enrolled ...
Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.